文献速递消化系统肿瘤

CD4 T细胞介导B2M缺失错配修复缺陷肿瘤的排斥

CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors.
PubMed 文献 · Cancer Discov · 2021-03-02

该研究在多种小鼠错配修复缺陷(MMRd)癌症模型中灭活B2m,发现MMRd B2m缺失细胞虽具致瘤性,但抗PD-1和抗CTLA4治疗可使其消退。免疫检查点抑制剂(ICPi)对MMRd B2m缺失肿瘤的疗效不依赖CD8+ T细胞,而依赖CD4+ T细胞;人肿瘤中B2M低表达者瘤内CD4+ T细胞增多。结论:B2M失活不削弱ICPi对MMRd肿瘤的疗效,并揭示CD4+ T细胞在肿瘤排斥中的独特作用。

要点

  • B2M失活不削弱ICPi对MMRd肿瘤的疗效
  • MMRd B2m缺失肿瘤经抗PD-1/CTLA4治疗可消退
  • 疗效依赖CD4+ T细胞而非CD8+ T细胞

核心结论

  • B2M失活不削弱免疫检查点抑制剂对错配修复缺陷肿瘤的疗效。
  • CD4+ T细胞在MMRd B2m缺失肿瘤的排斥中起独特作用。

研究设计与样本

  • 在多种小鼠MMRd癌症模型中灭活B2m。
  • 使用抗PD-1和抗CTLA4治疗MMRd B2m缺失肿瘤。

主要发现

  • MMRd B2m缺失细胞具致瘤性,但经抗PD-1和抗CTLA4治疗后退缩。
  • ICPi对MMRd B2m缺失肿瘤的疗效不依赖CD8+ T细胞,而依赖CD4+ T细胞。
  • 人肿瘤中B2M低表达者瘤内CD4+ T细胞增多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inactivation of beta-2 microglobulin (B2M) is considered a determinant of resistance to immune checkpoint inhibitors (ICPi) in melanoma and lung cancers. In contrast, B2M loss does not appear to affect response to ICPis in mismatch repair-deficient (MMRd) colorectal tumors where biallelic inactivation of B2M is frequently observed. We inactivated B2m in multiple murine MMRd cancer models. Although MMRd cells would not readily grow in immunocompetent mice, MMRd B2m null cells were tumorigenic and regressed when treated with anti-PD-1 and anti-CTLA4. The efficacy of ICPis against MMRd B2m null tumors did not require CD8+ T cells but relied on the presence of CD4+ T cells. Human tumors expressing low levels of B2M display increased intratumoral CD4+ T cells. We conclude that B2M inactivation does not blunt the efficacy of ICPi in MMRd tumors, and we identify a unique role for CD4+ T cells in tumor rejection. SIGNIFICANCE: B2M alterations, which impair antigen presentation, occur frequently in microsatellite-unstable colorectal cancers. Although in melanoma and lung cancers B2M loss is a mechanism of resistance to immune checkpoint blockade, we show that MMRd tumors respond to ICPis through CD4+ T-cell activation.This article is highlighted in the In This Issue feature, p. 1601.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Germano G, Lu S, Rospo G, et al. CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. Cancer Discov. 2021. PMID: 33653693. doi:10.1158/2159-8290.CD-20-0987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。